HRP20131116T1 - Derivati kinolina kao antibakterijska sredstva - Google Patents

Derivati kinolina kao antibakterijska sredstva Download PDF

Info

Publication number
HRP20131116T1
HRP20131116T1 HRP20131116TT HRP20131116T HRP20131116T1 HR P20131116 T1 HRP20131116 T1 HR P20131116T1 HR P20131116T T HRP20131116T T HR P20131116TT HR P20131116 T HRP20131116 T HR P20131116T HR P20131116 T1 HRP20131116 T1 HR P20131116T1
Authority
HR
Croatia
Prior art keywords
alkyl
compound
het
use according
bacterial infection
Prior art date
Application number
HRP20131116TT
Other languages
English (en)
Croatian (hr)
Inventor
Koenraad Jozef Lodewijk Marcel Andries
Anil Koul
Jérôme Emile Georges GUILLEMONT
Elisabeth Thérese Jeanne Pasquier
David Francis Alain LANÇOIS
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35768940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20131116(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HRP20131116T1 publication Critical patent/HRP20131116T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20131116TT 2005-08-03 2006-07-31 Derivati kinolina kao antibakterijska sredstva HRP20131116T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05107159 2005-08-03
PCT/EP2006/064856 WO2007014940A2 (en) 2005-08-03 2006-07-31 Quinoline derivatives as antibacterical agents

Publications (1)

Publication Number Publication Date
HRP20131116T1 true HRP20131116T1 (hr) 2013-12-20

Family

ID=35768940

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20131116TT HRP20131116T1 (hr) 2005-08-03 2006-07-31 Derivati kinolina kao antibakterijska sredstva

Country Status (28)

Country Link
US (1) US8017606B2 (enExample)
EP (1) EP1912647B1 (enExample)
JP (1) JP5410753B2 (enExample)
KR (1) KR101337237B1 (enExample)
CN (1) CN101277695B (enExample)
AR (1) AR054889A1 (enExample)
AU (1) AU2006274879B2 (enExample)
BR (1) BRPI0614524B8 (enExample)
CA (1) CA2615901C (enExample)
CY (1) CY1114908T1 (enExample)
DK (1) DK1912647T3 (enExample)
EA (1) EA014832B1 (enExample)
ES (1) ES2437575T3 (enExample)
HR (1) HRP20131116T1 (enExample)
IL (1) IL189141A (enExample)
JO (1) JO2952B1 (enExample)
MX (1) MX2008001602A (enExample)
MY (1) MY148241A (enExample)
NO (1) NO341247B1 (enExample)
NZ (1) NZ565283A (enExample)
PL (1) PL1912647T3 (enExample)
PT (1) PT1912647E (enExample)
RS (1) RS53065B (enExample)
SI (1) SI1912647T1 (enExample)
TW (1) TWI381839B (enExample)
UA (1) UA95916C2 (enExample)
WO (1) WO2007014940A2 (enExample)
ZA (1) ZA200801108B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2512364B2 (ja) 1992-03-02 1996-07-03 共栄電工株式会社 筒状の被加工物の内面研磨方法および装置
ATE444068T1 (de) * 2004-01-23 2009-10-15 Janssen Pharmaceutica Nv Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren
JO2952B1 (en) 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
WO2009091324A1 (en) * 2008-01-14 2009-07-23 Jyoti Chattopadhyaya Quinoline, naphthalene and conformationally constrained quinoline or naphthalene derivates as anti-mycobacterial agents
JP5246715B2 (ja) 2009-01-27 2013-07-24 独立行政法人科学技術振興機構 蛋白質架橋阻害剤およびその用途
WO2010144102A1 (en) * 2009-06-09 2010-12-16 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Material Command Pentafluorosulfanyl analogs of mefloquine
PL2841425T3 (pl) 2012-04-27 2016-10-31 Antybakteryjne pochodne chinoliny
US9617244B2 (en) 2012-04-27 2017-04-11 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
KR20150070347A (ko) 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. Ror-감마-t의 메틸렌 결합 퀴놀리닐 조절제
HK1213250A1 (zh) 2012-10-16 2016-06-30 Janssen Pharmaceutica, N.V. RORγT的雜芳基連接的喹啉基調節劑
ES2628365T3 (es) 2012-10-16 2017-08-02 Janssen Pharmaceutica N.V. Moduladores de quinolinilo unidos a fenilo de ROR-GAMA-T
US9642858B2 (en) 2012-10-30 2017-05-09 University of Pittsburgh—of the Commonwealth System of Higher Education Use of resazurin, or analogs thereof, for antibacterial therapy
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
CN105636952A (zh) 2013-10-15 2016-06-01 詹森药业有限公司 Rorγt的仲醇喹啉基调节剂
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
AU2014334619A1 (en) 2013-10-15 2016-04-21 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORyt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
KR20160068956A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyT의 퀴놀리닐 조절제
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
GB201904796D0 (en) * 2019-04-04 2019-05-22 Univ Sheffield Antimicrobial agent
AR121682A1 (es) * 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
AR121683A1 (es) * 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317491D0 (en) 1993-08-23 1993-10-06 Fujisawa Pharmaceutical Co New compound and a process for preparation thereof
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6376670B1 (en) * 1997-06-19 2002-04-23 Sepracor Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
GB9914486D0 (en) * 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
GB9917408D0 (en) * 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB0101577D0 (en) * 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
AR040336A1 (es) * 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
DK2301544T3 (da) * 2002-07-25 2013-01-02 Janssen Pharmaceutica Nv Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer
BR0315221A (pt) * 2002-10-10 2005-08-23 Morphochem Ag Komb Chemie Compostos com atividade antibacteriana
DE10316081A1 (de) * 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
NZ546990A (en) * 2003-11-20 2010-03-26 Janssen Pharmaceutica Nv 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors
SG151249A1 (en) * 2003-12-05 2009-04-30 Janssen Pharmaceutica Nv 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
ATE444068T1 (de) * 2004-01-23 2009-10-15 Janssen Pharmaceutica Nv Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren
JO2952B1 (en) 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents

Also Published As

Publication number Publication date
US20080255116A1 (en) 2008-10-16
BRPI0614524B8 (pt) 2021-05-25
CN101277695B (zh) 2011-12-14
JP5410753B2 (ja) 2014-02-05
PT1912647E (pt) 2013-12-05
CN101277695A (zh) 2008-10-01
NO20080955L (no) 2008-02-25
AU2006274879A1 (en) 2007-02-08
JP2009503024A (ja) 2009-01-29
EA014832B1 (ru) 2011-02-28
EP1912647A2 (en) 2008-04-23
EA200800501A1 (ru) 2008-10-30
NO341247B1 (no) 2017-09-25
KR101337237B1 (ko) 2013-12-06
KR20080038380A (ko) 2008-05-06
NZ565283A (en) 2011-07-29
IL189141A0 (en) 2008-08-07
WO2007014940A3 (en) 2007-03-29
WO2007014940A8 (en) 2007-07-05
SI1912647T1 (sl) 2014-01-31
BRPI0614524B1 (pt) 2020-05-19
MX2008001602A (es) 2008-02-19
TW200744594A (en) 2007-12-16
UA95916C2 (ru) 2011-09-26
TWI381839B (zh) 2013-01-11
DK1912647T3 (da) 2013-12-02
CA2615901A1 (en) 2007-02-08
US8017606B2 (en) 2011-09-13
ES2437575T3 (es) 2014-01-13
AR054889A1 (es) 2007-07-25
CY1114908T1 (el) 2016-12-14
IL189141A (en) 2015-10-29
HK1124233A1 (en) 2009-07-10
CA2615901C (en) 2014-06-03
PL1912647T3 (pl) 2014-02-28
BRPI0614524A2 (pt) 2011-04-05
MY148241A (en) 2013-03-29
WO2007014940A2 (en) 2007-02-08
JO2952B1 (en) 2016-03-15
RS53065B (sr) 2014-04-30
AU2006274879B2 (en) 2013-01-10
ZA200801108B (en) 2009-05-27
EP1912647B1 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
HRP20131116T1 (hr) Derivati kinolina kao antibakterijska sredstva
JP2009503024A5 (enExample)
HRP20160585T1 (hr) Antibakterijski derivati kinolina
HRP20110392T1 (hr) Derivati kinolina za liječenje latentne tuberkuloze
HRP20140206T1 (hr) Derivati kinolina kao antibakterijska sredstva
HRP20090673T1 (hr) Derivati kvinolina i njihova uporaba kao mikobakterijskih inhibitora
HRP20240861T1 (hr) Derivati 6-(4-amino-3-metil-2-oksa-8-azaspiro[4.5]dekan-8-il)-3-(2,3-dihlorofenil)-2-metilpirimidin-4(3h)-ona i srodni spojevi kao inhibitori ptpn11 (shp2) za liječenje raka
JP2009503025A5 (enExample)
CA2554049A1 (en) Quinoline derivatives for use as mycobacterial inhibitors
HRP20151111T1 (hr) Kinuklidinski spojevi kao ligandi nikotinskog acetilkolin alfa-7 receptora
CA2566544A1 (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
CA2478229A1 (en) Pyridinoylpiperidines as 5-ht1f agonists
NO20081026L (no) Kinolinderivater som antibakterielle midler
HRP20141108T1 (hr) Antagonisti piperidinon karboksamid azaindan cgrp receptora
HRP20210484T1 (hr) Antimikrobna sredstva koja se temelje na imidazolu
HRP20201023T1 (hr) Dioksilan analozi uridina za liječenje raka
HRP20220446T1 (hr) Lijekovi inhibitora membranskog antigena specifičnog za prostatu (psma)
HRP20171793T1 (hr) Farmaceutske formulacije koje sadrže kristalne oblike (r)-7-kloro-n-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamid hidroklorid monohidrata
HRP20100428T1 (hr) Antibakterijski derivati kvinolina
JP2010511667A5 (enExample)
ME01245B (me) Antibakterijski hinolinski derivati
HRP20120910T1 (hr) Derivati kinolina kao antibakterijska sredstva
HRP20170044T1 (hr) Derivati kinolina kao antibakterijska sredstva
JP2010511671A5 (enExample)
AR069743A1 (es) Derivados de pirazol como inhibidores de 5-lipoxigenasa